Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PEG-Asparaginase · 1 trial · 1 indication
To determine the safety and feasibility of treatment with everolimus in combination with vincristine, prednisone, PEG-asparaginase and doxorubicin in patients with relapsed acute lymphoblastic leukemia (ALL)
| Name | Type | Description |
|---|---|---|
| Everolimus | DRUG | Orally, daily days 1-32 per assigned dose level |
| Prednisone | DRUG | 40 mg/m2/day orally 3 x daily days 4-32 |
| Vincristine | DRUG | 1.5 mg/m2 IV daily on days 4, 11, 18, and 25 |
| PEG-Asparaginase | DRUG | 2,500 U/m2 IV 1 x daily on days 5 and 18 |
| Doxorubicin | DRUG | 30 mg/m2 IV on days 4 and 5 |
| Dexrazoxane | DRUG | 300 mg/m2 IV on days 4 and 5 |
Inclusion Criteria: * ALL in first bone marrow relapse occuring \> 18 months from initial diagnosis * Normal organ function * Maximum prior cumulative doxorubicin dose of \</= 360 mg/m2 or equivalent Exclusion Criteria: * Prior therapy for ALL except for intrathecal (IT) chemotherapy * Pregnant o...
PEG-Asparaginase is used for the treatment of Acute Lymphoblastic Leukemia (ALL). It is being studied as part of a multiagent re-induction chemotherapy regimen in pediatric patients with ALL. The drug is currently in Phase 1 clinical development and is considered investigational.
PEG-Asparaginase is developed by Novartis AG, which is publicly traded under the ticker symbol NVS. The company is conducting clinical research on this drug for the treatment of Acute Lymphoblastic Leukemia.
PEG-Asparaginase is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 clinical trial has been completed, with no active trials currently ongoing.
PEG-Asparaginase has been studied in one completed clinical trial, identified as NCT01523977. This Phase 1 trial, titled 'Everolimus With Multiagent Re-Induction Chemotherapy in Pediatric Patients With ALL,' enrolled 22 participants in the United States.
PEG-Asparaginase is a small molecule drug. It is being investigated for its role in treating Acute Lymphoblastic Leukemia, though its specific molecular target has not been disclosed in available information.